Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in riā¦ read more
Healthcare
Drug ManufacturersāGeneral
53 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$59.60
Price-3.45%
-$2.13
1Y
Price
Market Cap
$121.374b
Large
Price/Earnings 3y Avg5y Avg
17.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+17.6%
EBITDA Margin+8.7%
Net Profit Margin+12.8%
Free Cash Flow Margin+17.6%
EBITDA Margin+8.7%
Net Profit Margin+12.8%
Free Cash Flow MarginRevenue
$48.194b
-0.2%
1y CAGR+1.5%
3y CAGR+1.0%
5y CAGREarnings
$7.053b
+178.8%
1y CAGR-1.9%
3y CAGR-3.8%
5y CAGREPS
$3.45
+178.2%
1y CAGR-1.7%
3y CAGR-2.7%
5y CAGRBook Value
$18.506b
$90.038b
Assets$71.532b
Liabilities$47.139b
DebtDebt to Assets
52.3%
3.2x
Debt to EBITDAFree Cash Flow
$12.845b
-7.9%
1y CAGR+2.7%
3y CAGR-3.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company